12:00 AM
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Olysio simeprevir: Phase IIa started

Medivir said J&J began an open-label Phase IIa trial to evaluate an all-oral regimen of 75 mg simeprevir, 450 mg TMC647055 and 30 or 60 mg JNJ56914845 plus a low dose of ritonavir each given once daily for 12 weeks in about 40 patients with chronic HCV genotype 1 infection who are either treatment-naïve or who...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >